NCT03594955View on ClinicalTrials.gov

First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

February 6, 2021

Study Completion Date

February 6, 2021

Conditions
Leukaemia
Interventions
DRUG

SAR440234

Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous

Trial Locations (4)

13273

Investigational Site Number 2500004, Marseille

75010

Investigational Site Number 2500001, Paris

77030

Investigational Site Number 8400001, Houston

94805

Investigational Site Number 2500003, Villejuif

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT03594955 - First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter